Uppsala, Sweden, March 26, 2021 – Oasmia Pharmaceutical AB, an innovation-focused specialty pharmaceutical company is pleased to announce that it will be presenting final data from the dose-escalation and dose-expansion cohorts of the Phase I trial of Cantrixil at the American Association of Cancer Research (AACR) annual meeting which is being held virtually on April 10-15 and May 17-21.
Details of the abstract and presentation are as follows:
Abstract Control Number: 5183
Title: TRX-E-002-1 in treatment-refractory ovarian cancer: Final phase 1 study results from the dose-escalation and dose-expansion cohorts
Presenter: Jermaine Coward, MBBS PhD, ICON Cancer Centre, South Brisbane, QLD, Australia
Session Title: Targeted Therapy and Ovarian Cancer Trials
Presentation Number: CT012
Presentation Type: 15-minute oral presentation
Date and Time: Sunday Apr 11, 2021 2:00 PM – 3:45 PM (U.S. ET) : Monday Apr 12, 2021 4:00 AM – 5:45 AM (Eastern Australian Time)
For more details, please access the AACR annual meeting website online here.
Oasmia recently announced that it signed an agreement with Kazia Therapeutics, an Australian oncology-focused biotechnology company, to acquire exclusive global development rights for Cantrixil, a product candidate in development intended for the treatment of ovarian cancer.
Cantrixil consists of the active molecule, a potent and selective third generation benzopyran SMETI inhibitor named TRXE-002-01, encapsulated in a cyclodextrin. It is believed to target a wide spectrum of cancer cells, including chemotherapy-resistant tumor-initiating cells that are thought to be responsible for disease relapse. In December 2020, Kazia released the top-line results of a Phase I open-label study (NCT02903771) conducted at sites in the USA and Australia. The Phase I study met its primary endpoints, establishing clinical proof of concept, subject to further clinical evaluation and confirmation.
For More Information:
Oasmia Pharmaceutical AB
Francois Martelet, Chief Executive Officer
Phone: +46 18-50 54 40
E-mail: IR@oasmia.com
Consilium Strategic Communications (For Oasmia)
Jonathan Birt, Chris Welsh, Ashley Tapp
Phone: +44 (0)20 3709 5700
E-mail: oasmia@consilium-comms.com
About Oasmia Pharmaceutical AB
Oasmia is a specialty pharma company dedicated to improving the lives of patients by enhancing the intravenous delivery of established and novel drugs in significant diseases, including cancer. Product development is based on Oasmia’s proprietary drug delivery platform ™ which can be applied to medicines used in many therapeutic areas, to develop water soluble formulations of drugs that currently require chemical solubilizers for dissolution. The first product approved using this technology is Apealea® (paclitaxel micellar). Apealea has received market authorization in the European Union and several other territories for the treatment of first relapse in platinum-sensitive ovarian cancer, in combination with carboplatin. The Company is making Apealea accessible to patients through its partnership with Elevar Therapeutics, together with its existing commercial operations in the Nordic region. Oasmia’s shares are traded on the Nasdaq Stockholm stock exchange (ticker: OASM). To find out more about Oasmia please visit www.vivesto.com.